rTR Technovation’s mission is to put an end to lifetime disease and prescription management of inflammation-based chronic diseases. Our first patented technology focuses on the $131B hypertension market, where we have proof of concept of anchoring to the blood vessel wall at early stages of inflammation, allowing local drug delivery directly to the site with fewer side effects.